Latest Clinically Impactful Updates in Internal Medicine
The most significant recent updates in internal medicine center on expanded treatment options for inflammatory bowel disease, refined approaches to managing multimorbidity and polypharmacy, and emerging evidence in cardiovascular disease, metabolic conditions, and diagnostic innovations across gastroenterology and hepatology. 1, 2, 3, 4
Key Updates by Clinical Domain
Inflammatory Bowel Disease - Major Therapeutic Advances
The 2024 AGA guidelines represent a substantial expansion of treatment options for moderate-to-severe ulcerative colitis 1:
For advanced therapy-naïve patients with moderate-to-severe UC, multiple new agents now have moderate-to-high certainty evidence supporting their use, with upadacitinib demonstrating the highest efficacy (large desirable effect with 20% improvement over placebo). 1
The treatment landscape now includes:
- High certainty evidence: Upadacitinib (superior efficacy for both induction and maintenance)
- Moderate certainty evidence: Infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, filgotinib, ustekinumab, ozanimod, etrasimod, mirikizumab, risankizumab, and guselkumab 1
Critical regulatory considerations:
- In the United States, FDA restricts JAK inhibitors (tofacitinib, filgotinib, upadacitinib) to patients who have failed or are intolerant to TNF antagonists 1
- In Europe, the EMA recommends cautious first-line use of JAK inhibitors in patients ≥65 years, current/former long-term smokers, or those with cardiovascular disease or cancer history 1
Practical implementation points:
- Biosimilars of infliximab, adalimumab, and ustekinumab are equivalent to originators in efficacy 1
- Subcutaneous formulations of infliximab and vedolizumab show comparable efficacy to intravenous maintenance 1
- Extended induction regimens (up to 16 weeks) or dose escalation may benefit patients with severe disease 1
Multimorbidity and Polypharmacy Management
The 2019 systematic guideline review established evidence-based frameworks for managing complex patients 5:
For adults with multimorbidity, identify those at risk for adverse events (unplanned hospitalization, care home admission) using prognostic models during routine care, then implement individualized management focused on patient preferences and thorough assessment of drug interactions. 5
The evidence synthesis of 246 recommendations across 8 high-quality guidelines emphasizes:
- Target patients with ≥1 long-term condition where management has become burdensome 5
- Prioritize quality of life outcomes through shared decision-making based on what matters most to each patient regarding treatments and health priorities 5
- Conduct systematic medication reviews focusing on drug-drug interactions and deprescribing opportunities 5
Emerging Evidence Across Multiple Domains
Recent practice-changing literature from 2024-2025 highlights advances in 2, 3, 4, 6:
Cardiovascular disease: New diagnostic and therapeutic approaches Metabolic conditions: Expanded use of incretin therapies (GLP-1 and GIP agonists) for obesity and metabolic-associated steatohepatitis Gastroenterology:
- Novel blood and stool markers for colorectal cancer screening 4
- New diagnostic approaches for pancreatic ductal adenocarcinoma 4
- Immunotherapy for locally advanced mismatch repair-deficient colorectal cancer 4
- Treatment advances for eosinophilic esophagitis and primary biliary cholangitis 4
Infectious diseases and hematology: Significant therapeutic updates 6 Artificial intelligence: Growing impact on diagnosis and patient management 6
Hospital-Based Internal Medicine Evolution
The optimal model for general internal medicine focuses on the "generalist-specialist" approach, where internists coordinate care for undifferentiated, complex, and multimorbid patients while liaising with subspecialties, rather than serving as a catch-all service. 7
This framework addresses:
- Management of undifferentiated presentations requiring diagnostic expertise
- Complex multimorbid patients needing holistic coordination
- Development of robust hospital-at-home services 7
- Quality improvement and educational leadership within medical systems 7
Common Pitfalls to Avoid
JAK inhibitor prescribing: Do not use as first-line in the US without prior TNF antagonist failure; exercise caution in Europe for high-risk cardiovascular patients 1
Multimorbidity management: Avoid fragmented subspecialty-only care without a coordinating internist assessing overall medication burden and patient priorities 5
Biosimilar hesitancy: Do not avoid biosimilars due to unfounded efficacy concerns—they are therapeutically equivalent 1
Premature treatment discontinuation: Consider extended induction regimens or dose escalation before declaring treatment failure in severe UC 1